Compare Dollar General Corp. (DG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs ResMed Inc. — how do they compare? Dollar General Corp. trades at $119.35 (market cap $26.49B), while ResMed Inc. trades at $222.55 (market cap $32.61B). The key difference: ResMed Inc. is the larger of the two by market cap, and Dollar General Corp. pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| DG | RMD | |
|---|---|---|
Market Cap | $26.49B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $293.73 |
52-Week Low | $95.94 | $182.82 |
Enterprise Value | $40.93B | $31.97B |
Dividend Yield | 1.97% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.39, down 3.32% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.00 surpassing the $1.89 expectation. Positive cash flow trends and a declining debt-to-asset ratio (20.03 in 2025) support financial health. A dividend of $0.59 is scheduled for payment on July 21, 2026.
The outlook is cautiously optimistic, with a consensus price target of $128.45 offering ~5% upside. Analyst sentiment is bullish (52% Buy ratings), but risks include competitive pressure from Walmart and Amazon, margin compression from rising costs, and market saturation. Revenue growth is projected to reach $43.1B in 2026, though net margin remains thin at 3.63%.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
